GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » PB Ratio

Gyre Therapeutics (Gyre Therapeutics) PB Ratio : (As of May. 15, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-15), Gyre Therapeutics's share price is $15.63. Gyre Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $-0.21. Hence, Gyre Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Gyre Therapeutics's PB Ratio or its related term are showing as below:

During the past 3 years, Gyre Therapeutics's highest PB Ratio was 53.48. The lowest was 11.64. And the median was 37.42.

GYRE's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.52
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Gyre Therapeutics's average Book Value Per Share Growth Rate was -137.30% per year.

Back to Basics: PB Ratio


Gyre Therapeutics PB Ratio Historical Data

The historical data trend for Gyre Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics PB Ratio Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
PB Ratio
- - -

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
PB Ratio - - -

Competitive Comparison of Gyre Therapeutics's PB Ratio

For the Biotechnology subindustry, Gyre Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's PB Ratio falls into.



Gyre Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Gyre Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=15.63/-0.207
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Gyre Therapeutics  (NAS:GYRE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Gyre Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics (Gyre Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines